Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase NA 4Phase 3 4Phase 2 4Phase EARLY_PHASE1 2Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Multiple Myeloma 25Breast Neoplasms 21Colorectal Neoplasms 17Neoplasms 16Prostatic Neoplasms 15Lymphoma, B-Cell 15Stomach Neoplasms 13Carcinoma, Hepatocellular 12Recurrence 11Pancreatic Neoplasms 11Lung Neoplasms 11Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 11Solid Tumor 10Uterine Cervical Neoplasms 9Lymphoma, Non-Hodgkin 9Glioblastoma 9Leukemia 8Ovarian Neoplasms 7Glioma 7Sarcoma 6Polycystic Ovary Syndrome 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Hematologic Neoplasms 5Head and Neck Neoplasms 5Neuroendocrine Tumors 4Lymphoma, T-Cell, Peripheral 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Unknown × Myeloproliferative Disorders × Clear all
NCT03795779 2021-05-19

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

iCell Gene Therapeutics

Phase EARLY_PHASE1 Unknown
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04156256 2019-11-12

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

iCell Gene Therapeutics

Phase EARLY_PHASE1 Unknown
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡